Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators

Oncogene

Volumn 29, Issue 23, 2010, Pages 3335-3348

  Wang, S E ^a   Yu, Y ^b   Criswell, T L ^c   Debusk, L M ^c   Lin, P C ^c   Zent, R ^c   Johnson, D H ^c   Ren, X ^b   Arteaga, C L ^c,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR ligands; HER2 ErbB2; Ras; TGF ; Tumor microenvironment; VEGF

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUTANT PROTEIN; NERVE CELL ADHESION MOLECULE; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN;

ARTICLE; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

CELL LINE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953479867     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.112     Document Type: Article

References (55)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. (1998). Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phospha-tidylinositol-3 kinase. J Biol Chem 273: 28238-28246. (Pubitemid 28496122)
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
3. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C. (1997). Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem 272: 1429-1432. (Pubitemid 27043214)
4. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. (2002). p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115: 3193-3206.
5. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW et al. (1994). Auto-and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem 269: 22817-22822.
6. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME et al. (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27-36.
7. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. (2001). Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 276: 48679-48692.
8. Debnath J, Muthuswamy SK, Brugge JS. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
9. DeBusk LM, Hallahan DE, Lin PC. (2004). Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 298: 167-177.
10. Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
11. Dumont N, Arteaga CL. (2003). Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3: 531-536.
12. Erdogan M, Pozzi A, Bhowmick N, Moses HL, Zent R. (2007). Signaling pathways regulating TC21-induced tumorigenesis. J Biol Chem 282: 27713-27720.
13. Fahey MS, Paterson IC, Stone A, Collier AJ, Heung YL, Davies M et al. (1996). Dysregulation of autocrine TGF-beta isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts. Br J Cancer 74: 1074-1080.
14. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106.
15. Fritz G, Just I, Kaina B. (1999). Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687.
16. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655.
17. Heasley LE, Han SY. (2006). JNK regulation of oncogenesis. Mol Cells 21: 167-173.
18. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. (2002). Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156: 299-313.
19. Josko J, Mazurek M. (2004). Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10: RA89-RA98.
20. Kim ES, Kim MS, Moon A. (2005). Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine 29: 84-91.
21. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB et al. (1990). Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497.
22. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP et al. (2006). Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12: 57-61.
23. Lo RS, Wotton D, Massague J. (2001). Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J 20: 128-136.
24. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. (2000). Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblasto-ma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 60: 5879-5886.
25. Malipiero U, Holler M, Werner U, Fontana A. (1990). Sequence analysis of the promoter region of the glioblastoma derived T cell suppressor factor/transforming growth factor (TGF)-beta 2 gene reveals striking differences to the TGF-beta 1 and-beta 3 genes. Biochem Biophys Res Commun 171: 1145-1151.
26. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor (Iressa) inhibits HER2/neu (erbB2)-over-expressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895.
27. Mucsi I, Skorecki KL, Goldberg HJ. (1996). Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta1 on gene expression. J Biol Chem 271: 16567-16572. (Pubitemid 26239011)
28. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE et al. (2003). Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23: 8691-8703.
29. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH et al. (2004). Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64: 9002-9011.
30. Normanno N, Bianco C, De Luca A, Salomon DS. (2001). The role of EGF-related peptides in tumor growth. Front Biosci 6: D685-D707.
31. Oft M, Akhurst RJ, Balmain A. (2002). Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 4: 487-494.
32. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D et al. (2005). Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44: 2293-2304.
33. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al. (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467. (Pubitemid 26151185)
34. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94.
35. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C. (2001). Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535.
36. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson Jr T et al. (2004). Synthesis and activity of new aryl-and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 14: 3581-3584.
37. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H et al. (2000). Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19: 3013-3020.
38. Seton-Rogers SE, Lu Y, Hines LM, Koundinya M, LaBaer J, Muthuswamy SK et al. (2004). Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 101: 1257-1262.
39. Sharma SV, Bell DW, Settleman J, Haber DA. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
40. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. (2005). Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
41. Shirakata Y, Komurasaki T, Toyoda H, Hanakawa Y, Yamasaki K, Tokumaru S et al. (2000). Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 275: 5748-5753.
42. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435.
43. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
44. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. (2004). Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505-24513.
45. Wagner EF, Nebreda AR. (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
46. Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V et al. (1998). ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci USA 95: 6809-6814.
47. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. (2006a). HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25-38.
48. Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. (2006b). HER2/Neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor {beta}. Cancer Res 66: 9591-9600.
49. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. (2005). Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} fun. Mol Cell Biol 25: 4703-4715.
50. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH et al. (2008). Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpres-sing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605-5620.
51. Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Haring HU, Schleicher ED. (2000). AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol 11: 2007-2016.
52. Willis BC, Borok Z. (2007). TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293: L525-L534.
53. Worthylake R, Opresko LK, Wiley HS. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865-8874.
54. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
55. Ye D, Mendelsohn J, Fan Z. (1999). Augmentation of a humanized anti-HER2mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731-738.